A phase II dose-ranging study of mirabegron in patients with overactive bladder

被引：0
|
作者：
Christopher R. Chapple
Vladimir Dvorak
Pjotr Radziszewski
Philip Van Kerrebroeck
Jean Jacques Wyndaele
Brigitte Bosman
Peter Boerrigter
Ted Drogendijk
Arwin Ridder
Ingrid Van Der Putten-Slob
Osamu Yamaguchi
机构：
[1] Sheffield Teaching Hospitals,Department of Urology, Royal Hallamshire Hospital
[2] Centrum ambulantní gynekologie a primární péce,Department of Urology
[3] Medical University Warsaw,Department Urology
[4] Maastricht University Medical Center,Department of Urology
[5] Antwerp University and Antwerp University Hospital,Division of Bioengineering and LUTD Research, School of Engineering
[6] Astellas Pharma Europe BV,undefined
[7] Nihon University,undefined
来源：
International Urogynecology Journal | 2013年 / 24卷
关键词：
β; -adrenoceptor agonist; Mirabegron; Overactive; Urinary bladder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1447 / 1458
页数：11
相关论文
共 50 条
  • [31] Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?
    Kinjo, Manami
    Masuda, Kazuki
    Nakamura, Yu
    Taguchi, Satoru
    Tambo, Mitsuhiro
    Fukuhara, Hiroshi
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2023, 34 (04) : 853 - 859
  • [32] Efficacy and safety of Solifenacin combined with Mirabegron in treating overactive bladder in female patients following bladder instillation for bladder cancer
    Zhang, Lichao
    Chen, Yinghua
    Liao, Huasheng
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2025, 17 (02): : 1144 - 1152
  • [33] Clinical use of the beta(3) adrenoceptor agonist mirabegron in patients with overactive bladder syndrome
    Marcus, Monika Vij
    Drake, Marcus J.
    THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (05) : 241 - 248
  • [34] Economic Impact Associated with Patients with Overactive Bladder on Drug Treatment with Mirabegron or Antimuscarinics in Spain
    Nunez, Aurora Ortiz
    de Almeida, Rodrigo Martins
    Arrom, Laura Mateu
    Terres, Carlos Rubio
    Rodriguez, Dario Rubio
    Blazquez, Ana Maria Mora
    ARCHIVOS ESPANOLES DE UROLOGIA, 2023, 76 (01): : 98 - 106
  • [35] Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
    Kwon, Se Yun
    Park, Dong Jin
    Seo, Young Jin
    Lee, Kyung Seop
    INVESTIGATIVE AND CLINICAL UROLOGY, 2020, 61 (04) : 419 - 424
  • [36] Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
    Kim, Seong Cheol
    Park, Myungchan
    Chae, Chongsok
    Yoon, Ji Hyung
    Kwon, Taekmin
    Park, Sejun
    Moon, Kyung Hyun
    Cheon, Sang Hyeon
    Park, Sungchan
    INVESTIGATIVE AND CLINICAL UROLOGY, 2021, 62 (03) : 317 - 323
  • [37] Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: A prospective study
    Vasudeva, Pawan
    Kumar, Amitabh
    Yadav, Siddharth
    Kumar, Niraj
    Chaudhry, Neera
    Prasad, Vishnu
    Nagendra Rao, Swatantra
    Yadav, Prashant
    Patel, Samarth
    NEUROUROLOGY AND URODYNAMICS, 2021, 40 (08) : 2041 - 2047
  • [38] Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)
    Rossanese, Marta
    Novara, Giacomo
    Challacombe, Ben
    Iannetti, Alessandro
    Dasgupta, Prokar
    Ficarra, Vincenzo
    BJU INTERNATIONAL, 2015, 115 (01) : 32 - 40
  • [39] Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo
    Chapple, Christopher R.
    Cruz, Francisco
    Cardozo, Linda
    Staskin, David
    Herschorn, Sender
    Choudhury, Nurul
    Stoelzel, Matthias
    Heesakkers, John
    Siddiqui, Emad
    EUROPEAN UROLOGY, 2020, 77 (01) : 119 - 128
  • [40] Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial
    Vik Khullar
    Javier Cambronero
    Javier C Angulo
    Marianne Wooning
    Mary Beth Blauwet
    Caroline Dorrepaal
    Nancy E Martin
    BMC Urology, 13
12345